Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11945273 | 0.93 | CYP3A4 (0.47) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11944410 | 0.91 | MAPT (0.57) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945116 | 0.88 | MAPT (0.49) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945004 | 0.88 | MAPT (0.49) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945348 | 0.88 | MAPT (0.52) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945376 | 0.87 | POLB (0.41) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL11945293 | 0.86 | CYP3A4 (0.47) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945370 | 0.86 | MAPT (0.40) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL11945347 | 0.84 | MAPT (0.52) | MAPTALDH1A1LMNADCTPP1KMT2A | |
| SCHEMBL11945364 | 0.84 | ALDH1A1 (0.39) | MAPTALDH1A1LMNADCTPP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | MAPT 2295/4885ALDH1A1 2437/4885LMNA 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.